Neoprobe 3rd Quarter 2011 Earnings And Business Update Conference Call Invitation
Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced it would report its financial results for the third quarter of 2011 on Wednesday, October 26, 2011 after market close. The announcement will be followed by a conference call with the investment community the following day, Thursday, October 27 at 8:30 am ET.
Neoprobe’s President and CEO, Dr. Mark Pykett, Senior Vice President, Pharmaceutical Research and Clinical Development, Dr. Fred Cope, and Senior Vice President and CFO, Brent Larson, will provide a development and business update and will discuss the Company’s financial results for the third quarter of 2011 during the conference call. The conference call can be accessed as follows:
|Conference Call Information|
|TO PARTICIPATE LIVE:||TO LISTEN TO A REPLAY:|
|Date: Time: Toll-free (U.S.) Dial in # : International Dial in # :||Oct 27, 2011 8:30 AM ET (877) 407-0778 (201) 689-8565||Available until: Toll-free (U.S.) Dial in # : International Dial in # : Replay passcode: Account #: Conference ID #:||Nov 10, 2011 (877) 660-6853 (201) 612-7415 286 381791|
Neoprobe Corporation (NYSE Amex: NEOP) is a biomedical company focused
on enhancing oncology patient care and improving patient benefit through
radiopharmaceutical product development. Neoprobe is actively developing
two radiopharmaceutical agent platforms – Lymphoseek® and RIGScanTM CR –
to help surgeons better identify and treat certain types of cancer.
Neoprobe’s subsidiary, Cira Biosciences, Inc., is also exploring
development of a patient-specific cellular therapy technology platform
called ACT. Neoprobe’s strategy is to deliver superior growth and
shareholder return by bringing to market novel radiopharmaceutical
agents and advancing the Company’s pipeline program through continued
investment and selective acquisitions. For more information, please
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV